Functional mapping of interacting regions of the photoreceptor phosphodiesterase (PDE6) γ-subunit with PDE6 catalytic dimer, transducin, and Regulator of G-protein Signaling9-1 (RGS9-1)

Xiu-Jun Zhang, Xiong-Zhuo Gao, Wei Yao, and Rick H. Cote

From the Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824

*Running title: Functional interaction sites of Pγ with PDE6 and transducin

To whom correspondence should be addressed: Rick H. Cote, Department of Molecular, Cellular, and Biomedical Science, University of New Hampshire, Durham, NH 03824, phone: 603-862-2458, FAX: 603-862-4013, rick.cote@unh.edu

**Keywords:** PDE6; Pγ; transducin; GTPase activity; enzyme regulation; visual transduction; photoreceptor; allosteric regulation; phosphodiesterase; cyclic GMP

**Background:** The PDE6 γ-subunit serves multiple functions during visual transduction. Several regions of Pγ that interact with PDE6 or transducin were identified. Multiple interacting sites of Pγ with PDE catalytic dimer, transducin and the transducin/RGS9 complex coordinate the activation and deactivation of PDE6. This work contributes to understanding how defects in PDE6 structure/function lead to retinal disease.

**Results:** Several regions of Pγ that interact with PDE6 or transducin were identified. The ability of Pγ to stimulate noncatalytic cGMP binding to the GAF domains of PDE6 has been localized to amino acids 27-30 of Pγ. Transducin activation of PDE6 catalysis critically depends on the presence of Ile54 in the glycine-rich region of Pγ in order to relieve inhibition of catalysis. The central glycine-rich region of Pγ is also required for transducin to increase cGMP exchange at the GAF domains. Finally, Thr65 and/or Val66 of Pγ are critical residues for Pγ to stimulate GTPase activity of transducin in a complex with RGS9-1. We propose that the glycine-rich region of Pγ is a primary docking site for PDE6-interacting proteins involved in the activation/inactivation pathways of visual transduction. This functional mapping of Pγ with its binding partners demonstrates the remarkable versatility of this multifunctional protein and its central role in regulating the activation and lifetime of visual transduction.

**Conclusion:** Multiple interacting sites of Pγ with PDE catalytic dimer, transducin and the transducin/RGS9 complex coordinate the activation and deactivation of PDE6.

**Significance:** Rod and cone photoreceptors respond to light by triggering a biochemical cascade leading to the activation of the cGMP-specific phosphodiesterase (PDE6). Because of its dominant role in controlling cGMP levels (and hence membrane conductance), the extent and duration of PDE6 activation must be precisely regulated. Catalytic activity of the rod PDE6 catalytic heterodimer (Pαβ) is directly regulated
by its inhibitory γ-subunits (Pγ) that tightly bind to Pαβ to inhibit catalysis in the dark-adapted photoreceptor cell (1). During the first steps in vision, photoisomerized rhodopsin activates transducin, which binds GTP and releases its activated α-subunit (Tα*-GTP) to activate the PDE6 holoenzyme (αβγγ) by relieving the inhibition by Pγ at the active sites of the enzyme. The recovery of the dark-adapted state requires inactivation of Tα*-GTP by its intrinsic GTPase activity which is the rate-limiting step for recovery of the photoreceptor. The GTPase rate of Tα*-GTP is modulated by the Regulator of G-protein Signaling 9-1 (RGS9-1) to which Pγ binds to potentiate the GTPase accelerating function of RGS9-1 (2). The importance of the proper functioning and regulation of these proteins is underscored by the fact that genetic disruptions of PDE6 or the proteins with which it interacts often result in a loss of visual function, photoreceptor degeneration, and/or blindness (3-5).

The 87-amino acid Pγ subunit (localized to the signal-transducing outer segment compartment of rod photoreceptors) is remarkable for the variety of regulatory functions it performs as well as the multitude of proteins with which it interacts in addition to the catalytic subunits of PDE6 (6). The primary regulatory role of Pγ is to regulate access of substrate to the catalytic pocket of PDE6 and thereby control cGMP hydrolytic rates. This function is carried out by the last few C-terminal residues of Pγ interacting with the PDE6 catalytic domains in the immediate vicinity of the active site (7-9). An allosterically mediated inhibition of catalysis that occurs in the absence of the C-terminal residues of Pγ has also been identified (10). Pγ also enhances the affinity with which cGMP binds to noncatalytic binding sites within the regulatory domain of the PDE6 catalytic dimer (11,12); the region of Pγ responsible for this effect is in the central region of the Pγ sequence which is known to have high affinity for the catalytic dimer (13-15). In addition to these two distinct functional regions, chemical cross-linking studies support the idea that Pγ binds in an extended conformation along the entire surface of the catalytic subunits (16,17), including both regulatory domains [GAFa and GAFb, named for their widespread occurrence in cGMP PDEs, certain adenylate cyclases, and the E. coli Fh1a protein (18)] and the catalytic domains.

The molecular mechanism by which activated transducin α-subunit interacts with Pγ to de-inhibit catalysis of the PDE6 holoenzyme is not well understood. Biochemical, structural and physiological studies support a model in which Tα*-GTP binds not only to the C-terminal tail of Pγ (to displace Pγ from occluding the PDE6 catalytic pocket), but also to several additional sites (most notably Trp70 and Leu76) within the last third of the Pγ sequence (19-26). However, Pαβ reconstituted with Pγ63-87 (i.e., the C-terminal fragment of Pγ consisting of amino acids 63 to 87) could not be activated by Tα*-GTPγS (10), indicating that additional sites of interaction of activated transducin with Pγ are required for activation of the PDE6 holoenzyme. The N-terminal half of Pγ (specifically amino acids 24-45) has been reported to interact with transducin α-subunit (27-30), and the greater efficiency with which cone versus rod PDE6 can be activated by transducin has been attributed to differences in the GAF binding interactions with Pγ (31). However, cross-linking and pull-down experiments suggest that Tα*-GTP interactions are weaker with the N-terminal half of Pγ than with the C-terminal region (26), raising questions about the functional significance of these interactions.

The recovery of the dark-adapted state following cessation of a light stimulus requires the inactivation of Tα*-GTP by its intrinsic GTPase activity; this reaction has been shown to be rate-limiting for the recovery of the rod photoreceptor (32). This GTPase rate is determined by a complex of proteins that include Tα*-GTP, RGS9-1, and other proteins (33); Pγ serves to facilitate the formation of a tighter complex of these proteins to potentiate the GTPase accelerating function of RGS9-1 (34-37). However, the interaction surface of Pγ with RGS9-1 and the functional significance of the interactions are unclear. Whereas biochemical and structural evidence shows that the C-terminal region of Pγ can bind to RGS9-1 (20,23,38), cross-linking and interaction assays have implicated the N-terminal half of Pγ in binding to the transducin/RGS9 complex (39). Furthermore, transgenic animals expressing a
phosphorylation-incompetent mutation at Thr35 of Pγ show altered photoresponse kinetics consistent with a disruption of the Pγ-mediated acceleration of GTPase activity by RGS9-1 (40).

In this paper, we used functional interaction assays to demonstrate that the intrinsically disordered Pγ subunit forms multiple stabilizing interactions with Pαβ that extend from the N-terminal region of Pγ (interacting with the cGMP binding site in the GAFa domain) to the last several C-terminal residues of Pγ (serving to occlude the active site in the catalytic domain), and including a newly discovered interaction region in the glycine-rich central portion of Pγ. We also localized the Pγ residues directly responsible enhancing the ability of cGMP to bind to the noncatalytic binding sites on the PDE6 catalytic dimer, and identified neighboring residues that stabilize this effect. Finally, we identified the structural requirements for Pγ to effectively interact with activated transducin in order to activate PDE6 catalysis (at the enzyme active site), to increase cGMP exchange (with noncatalytic binding sites in the regulatory GAFa domain), and to bind to the transducin/RGS9-1 complex (to accelerate the GTPase rate of the transducin α-subunit).

Together, these results provide a framework for understanding the sequential interactions of Pγ with PDE6 catalytic subunits and with its other binding partners that allow for precise temporal control of PDE activation and inactivation during visual transduction.

**EXPERIMENTAL PROCEDURES**

**Materials**—Bovine retinas were purchased from W. L. Lawson, Inc. Synthetic peptides Pγ10-30, Pγ19-30, Pγ21-30, Pγ63-87, Pγ65-87, and Pγ68-87 were purchased from New England Peptide. Ultima Gold scintillation fluid was from PerkinElmer Life & Analytical Sciences. Filtration membranes were from Millipore, the bicinchoninic acid protein assay reagents and immobilized glutathione were from Thermo Scientific/Pierce. All other chemicals were from Sigma-Aldrich (St. Louis, MO). [3H]cGMP and [γ-32P]GTP were from PerkinElmer Life & Analytical Sciences. The primers for constructing Pγ mutants were obtained from Invitrogen. The plasmid purification kits were from Qiagen.

**Construction of Pγ mutants**—Mutants lacking specific regions of the N-terminal sequence were constructed by PCR using primers designed to amplify various portions of the bovine rod Pγ sequence. The PCR products were inserted into the NotI and BamHI sites of pGEX-6P-1vector, and followed by transformation into the E. coli BL21/DE3 strain. The sequence of all Pγ mutants was confirmed by DNA sequencing at the Hubbard Center for Genome Studies (University of New Hampshire).

**Purification of Pγ mutants**—Following expression of recombinant Pγ mutants in E. coli BL21(DE3), the bacterial extract was purified by immobilized glutathione. The affinity-purified protein was treated with HRV3C protease to remove the glutathione-S-transferase fusion protein. Immobilized glutathione beads were added to the cleavage mix to remove any uncleaved protein and the cleaved glutathione-S-transferase. The Pγ mutants (containing five additional N-terminal amino acids derived from the fusion partner) were then further purified by C18 reverse-phase high pressure liquid chromatography. The purity (> 95 %) and size of these proteins were evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Protein concentrations were determined by the bicinchoninic acid protein assay (41) using bovine gamma globulin as a standard. In those Pγ constructs that were directly compared (e.g., full-length Pγ, Pγ67-87), we failed to observe an effect of the five additional N-terminal amino acids on Pγ inhibitory potency for Pαβ.

**PDE6 and Pαβ purification and functional assays**—Bovine rod PDE6 was purified from bovine retinas as described (42). Puβ catalytic dimers lacking Pγ were prepared by limited trypsin proteolysis and re-purified by Mono Q anion exchange chromatography prior to use (42). PDE6 catalytic activity was measured in 20 mM Tris, 10 mM MgCl2, 0.5 mg/ml bovine serum albumin, using a colorimetric assay (43). The PDE6 concentration was estimated based on
the rate of cGMP hydrolysis of trypsin-activated PDE6 and the knowledge of the $k_{cat}$ of the enzyme [5600 mol cGMP hydrolyzed per mol Paβ per s (44)].

The inhibition potency (IC$_{50}$) of synthetic peptides and Py truncation mutants was determined using 0.2 nM Paβ and 2 mM cGMP as substrates. Under these conditions, wild-type Py and N-terminal mutants up to Py21-87 inhibited Paβ in a stoichiometric manner, behavior consistent with previous studies (44,45).

$[^3]H$cGMP binding to PDE6 was measured with a filter binding assay (46). The maximum binding of $[^3]H$cGMP to nucleotide-depleted Paβ was typically between 1 to 2 mol cGMP per mol Paβ in the presence of wild-type Py. For measurements of cGMP dissociation kinetics, Paβ reconstituted with Py or Py mutants were first incubated with 1 µM $[^3]H$cGMP for 5 min at room temperature, and at time zero 1 mM unlabeled cGMP was added and samples were filtered at various times thereafter.

Preparation of Bovine Rod Outer Segments (ROS) and GTPase assay—Bovine rod outer segment (ROS) were prepared from commercial frozen bovine retinas on a step sucrose gradient using the standard method under dark condition (42) and stored at -80°C and used within a few weeks. For the transducin activation measurement, purified Paβ was pre-incubated with Py mutants or Py peptides at the indicated concentration to inhibit PDE activity (see Figure legends). Ten micromolar activated transducin (supplemented with 50 µM GTPγS) was added to above mixture and incubated for 5 minutes. The PDE activity was measured using 2 mM cGMP as substrate.

Data analysis—All experiments were repeated at least three times, and averages are reported as the mean ± S.E.M. Curve fitting was performed using SigmaPlot (SPSS, Inc.).

RESULTS AND DISCUSSION

Multiple regions of Py contribute to the high affinity with which Py inhibits catalysis—Previous studies have defined two distinct regions of Py that interact with PDE6 catalytic dimer, but did not account for the very high affinity of Py for the PDE6 catalytic dimer (see Introduction). We hypothesized that Py must contain as-yet undiscovered interacting sites which are responsible for stabilizing Py binding to Paβ. To test this, we generated a series of N-terminal truncated Py mutants, all of which contain the last ten amino acids as a reporter of the ability to inhibit catalysis. By comparing the relative binding affinity of various N-terminal truncated peptides, we discovered two new interaction “hotspots” for Py with Paβ. Fig. 1 shows that Py mutants lacking amino acid residues 27 to 38 showed a progressive, ~20-fold loss of binding affinity. A second region that stabilized Py binding to Paβ by ~15-fold was identified as Asp52-Asp53-Ile54 within the glycine-rich region of Py (Fig. 1). [A third set of stabilizing residues (Leu78-His79-Glu80) was previously identified in the C-terminal region (10).] In contrast, amino acid residues 1-26, 39-51 and 55-62 of Py showed little ability to stabilize the inhibition of catalysis at the active site (Fig. 1). We conclude from this analysis that three discrete regions of the Py sequence (i.e., polycationic region, glycine-rich region, and C-
terminal region) account for almost all of the favorable interactions that contribute to the high overall affinity of Py for the catalytic dimer of PDE6. An important physiological implication of these multiple Py-Pub stabilizing regions is that the Py subunit is very unlikely to interact with binding partners other than PDE6 in the dark-adapted state of the photoreceptor cell.

The ability of N-terminal Py fragments to augment inhibition of catalysis by the C-terminal region of Py—Previously we reported that a Py truncation mutant lacking the last 17 amino acids at its C-terminus (Py1-70) enhanced 100-fold the ability of a synthetic peptide (Py63-87) to inhibit catalysis; shorter truncation mutants (e.g., Py1-60) or smaller C-terminal peptides failed to exhibit this effect (10). To pinpoint the amino acids of Py responsible for this effect, we constructed several synthetic peptides (Py69-87, Py68-87 and Py67-87) and truncation mutants (Py1-67 and Py1-68). Testing various combinations of N-terminal and C-terminal fragments of Py, we found that Py1-68 in combination with Py68-87 was able to exhibit the same enhancement of inhibitory effectiveness as reported in the earlier study. This mixture of two Py fragments overlapping only at Cys68 have an overall binding affinity (IC\textsubscript{50} = 20 nM; Fig. 2) that is 100-fold less than the value for wild-type Py under the same experimental conditions.

To study the importance of the Cys68 residue that is shared by both Py fragments, we constructed site-directed mutants in which serine or alanine replacing the naturally occurring Cys68 terminal residue in the Py1-68 truncation mutant. We found that neither the Py1-68Ser nor the Py1-68Ala were able to enhance the effectiveness of the C-terminal Py68-87 peptide to inhibit Pub (data not shown). This led us to carefully evaluate the possibility that disulfide bond formation between the two Py fragments might be responsible for the enhanced inhibitory potency when Py1-68 and Py68-87 were incubated with Pub. To test this, we compared the behavior of identical mixtures of Pub and the two Py fragments in the presence or absence of 1 mM DTT. As shown in Fig. 2, Py1-68 failed to enhance the potency of Py68-87 in the presence of DTT, indicating that disulfide bond formation between the two fragments was responsible for the enhancement of inhibitory potency. Control experiments confirmed that 1 mM DTT had no effects on the apparent inhibitory potency of Py68-87 in the absence of the N-terminal Py fragment (data not shown). These results fail to support the idea that allosteric communication induced by the N-terminal fragment alters the conformation of the catalytic domain (10).

The ability of the N-terminal half of Py to enhance 50-fold the binding of Py68-87 when the two fragments are tethered to each other by a disulfide bond implies that substantial conformational flexibility likely exists between different regions of Py. Under this artificial circumstance, the N-terminal region anchors Py to the catalytic subunit, and brings the C-terminal region into proximity of the active site to permit inhibition of catalysis. The fact that the overall effectiveness of inhibition is 100-fold less than the wild-type protein implies that disruption of the local structure of Py caused by linking the two fragments by a disulfide bond impairs the ability of the C-terminal inhibitory residues to bind to the active site of the enzyme.

Important Py interaction sites with Pub to enhance cGMP binding to the GAF domain of PDE6—Having identified the important interacting residues of Py with PDE6 catalytic dimer to increase the inhibition potency, we next questioned to what extent these interaction sites contributed to the ability of Py to stabilize cGMP binding to the GAF domains of PDE6. To test this, we first measured the ability of a series of N-terminal truncated mutations to stabilize cGMP binding to the GAF domain of Pub. As shown in Fig. 3A, Py18-87 and Py21-87 were able to stimulate cGMP binding to the same extent as wild type Py and with a similar binding affinity (K\textsubscript{1/2} = 30-50 nM). Although the Py27-87 mutant was able to stimulate cGMP binding to Pub to the same maximum extent as wild type Py, the affinity was reduced 7-fold compared to Py21-87 (Fig. 3A). Removing two additional residues (Py29-87) reduced to one-half the maximum extent of stimulation of cGMP binding (Fig. 3A), while Py31-87 was ineffective (<20% stimulation; data not shown). We conclude from these N-terminal Py truncation mutants that amino acids 27-30 of Py...
are required to maximally stimulate cGMP binding to the GAFA domains of PDE6. Furthermore, neighboring amino acids (a.a. 21 through 26) enhance the local interactions between Pγ and the GAFA domain of Paβ that result in stimulation of cGMP binding.

To better define the region of Pγ responsible for stimulating cGMP binding to the GAFA domains of Paβ, we resorted to using small synthetic peptides of this region of Pγ. Although the shortest peptide we tested, Pγ21-30, contained the residues identified above as being important for stimulating cGMP binding (Fig. 3A), this 10-residue oligopeptide lacked sufficient affinity for Paβ to effectively induce this effect (≤ 20% stimulation of cGMP binding; data not shown). Full stimulation of cGMP binding by Pγ could be achieved if ten additional amino acids were present (Pγ10-20; Fig. 3B, see also ref. (15)). Partial (47%) restoration of Pγ-mediated cGMP binding was observed with a peptide of intermediate length, Pγ19-30, but with substantially lower peptide binding affinity (K_{1/2} = 280 μM; Fig. 3B). These results with Pγ synthetic peptides reveal for the first time that amino acid residues 10-18 within the N-terminal region of Pγ can play a local, stabilizing role in the ability of Pγ to stimulate cGMP binding to the GAFA domains of Paβ.

We conclude from these results that four amino acids (Pro27-Pro28-Lys29-Phe30) bordering the pro-rich and polycationic regions of Pγ are required to enhance cGMP binding affinity to the GAFA domains of Paβ. Neighboring residues on either side of this tetrapeptide provide local stabilizing interactions between Pγ and the Paβ GAF domains that enhance the effectiveness of this four-amino acid segment, consistent with chemical cross-linking studies showing interactions of Val21, Pro23 and Phe30 with the GAFA domains of the PDE6 catalytic subunits (16,17,50).

Pγ residue Ile54 is important for Ta*-GTPγS to relieve inhibition of PDE6 catalysis—Previous work demonstrated that activated transducin was incapable of relieving inhibition of catalysis resulting from binding of the C-terminal fragment (Pγ63-87) reconstituted with Paβ, suggesting that activated transducin required additional sites of interaction with Pγ in order to effectively de-inhibit PDE6 catalysis (10). To identify additional regions of Pγ responsible for the favorable interactions with Ta*-GTPγS leading to de-inhibition, we created a series of N-terminal truncation mutants that span the entire amino acid sequence of Pγ. These purified peptides were reconstituted with Paβ at concentrations sufficient to inhibit catalysis by 80% or greater (Fig. 4, solid bars). As expected, a short truncation of the N-terminal region (Pγ18-87) that retains the GAFA-interacting domain of Pγ was capable of effectively interacting with Ta*-GTPγS to relieve inhibition of PDE6 catalysis (Fig. 4, grey bars).

Unexpectedly, when Paβ was reconstituted with Pγ46-87 (which lacks the entire GAFA-interacting region), addition of activated transducin resulted in activation of PDE6 catalysis (Fig 4.). This demonstrates that the GAFA interacting region of Pγ is not a requirement for transducin activation of PDE6. Transducin also successfully de-inhibited Paβ reconstituted with Pγ52-87, Pγ53-87 and Pγ54-87 to the same maximum extent as wild type Pγ. However, Paβ reconstituted with Pγ55-87 was unable to be fully activated by Ta*-GTPγS, and shorter peptides (e.g., Pγ58-87) were also ineffective (<10% activation, Fig. 4). We conclude that Ile54 in the glycine-rich region of Pγ is essential for transducin to effectively interact with Pγ to displace the C-terminal region in order to fully activate PDE6 catalysis.

Ile54 of Pγ has been visualized in proximity to the Trp70 residue (important in the ability of Ta* to activate PDE6) in the crystal structure of a complex of a C-terminal Pγ fragment, a chimeric form of transducin α-subunit and the RGS domain of RGS9-1 (23). Chemical cross-linking studies have shown much more favorable interactions of the glycine-rich region of Pγ with PDE6 catalytic subunits compared to transducin (26). Together with our work, these results support the hypothesis that the glycine-rich region of Pγ plays a critical role in the transducin activation mechanism of PDE6. We propose that in the transition from the dark-adapted to light-activated state, the glycine-rich region of Pγ relays its interactions from the Paβ catalytic dimer to Ta* as it binds to the PDE6 holoenzyme. This “docking” of Ta* to the
glycine-rich region of Pγ (centering around Ile54) is necessary for Tα* to form additional interactions with the C-terminal region of Pγ (to displace the C-terminal region of Pγ from its binding sites in the catalytic pocket to de-inhibit catalysis) as well as the N-terminal half of Pγ (see next section).

**Interaction of Tα*-GTPγS with the glycine-rich region of Pγ increases the rate of cGMP dissociation from PDE6 GAFa domains**—The region of Pγ that stabilizes cGMP binding to the GAFa domains of Paβ (amino acids 21 to 30; see above) have also been reported to interact with transducin α-subunit based on binding assays of Pγ21-45 with Tα*-GTPγS (28,29). To directly test whether Tα*-GTPγS can alter cGMP binding to the GAFa domain through disrupting Paβ binding to Pγ, we measured the ability of Tα*-GTPγS to accelerate cGMP dissociation from Paβ reconstituted with various Pγ fragments. As shown in Fig. 5A, addition of Tα*-GTPγS to Paβ reconstituted with full-length Pγ increased 2.2 ± 0.2-fold (n = 4) the rate at which cGMP exchange occurs at the noncatalytic cGMP binding sites. Pγ1-60 was equally effective (2.2 ± 0.4-fold; n = 3) as wild-type in this regard (Fig. 5B). In contrast, Pγ1-45 reconstituted with Paβ showed virtually no stimulation of cGMP dissociation rate (1.2 ± 0.1-fold; n = 5) upon Tα*-GTPγS addition (Fig. 5C). We conclude that Tα*-GTPγS requires interactions with Pγ in the glycine-rich region (specifically a.a. 46 to 60) in order to weaken the interactions of Pγ in the region of amino acids 21-30 that are responsible for modulating cGMP affinity to the GAFa domains of PDE6. The ability of activated transducin α-subunit to accelerate cGMP dissociation may represent a negative feedback mechanism operating during light adaptation (see Conclusions).

**Characterization of the regions of Pγ important for facilitating deactivation of the complex of PDE6/transducin/RGS9-1**—Another important role of Pγ is to form a protein complex with RGS9-1, transducin, and other accessory proteins to accelerate the GTPase activity of activated transducin during deactivation of PDE6 (38). However, there is conflicting evidence regarding the sites of interaction of Pγ with this complex (see Introduction). To precisely define the Pγ residues required for GTPase acceleration, we first utilized a set of Pγ mutants truncated to various extents at the C-terminus. These Pγ mutants were incubated with ROS membranes and tested for their ability to accelerate the GTPase activity of transducin above the intrinsic activity of this membrane preparation. As shown in Fig. 6A, wild-type Pγ (Pγ1-87) and a mutant lacking the terminal Ile87 (Pγ1-86) both stimulated the GTPase rate by ~2.5-fold compared to the control lacking any exogenous Pγ. Removal of an additional amino acid (Pγ1-85) slowed the GTPase rate by 60% compared to full length Pγ, consistent with a previous study (20). We conclude that a single amino acid, Ile86, is critical for the ability of Pγ to potentiate GTPase acceleration.

Larger C-terminal truncations of Pγ [e.g., Pγ1-70 (not shown) or Pγ1-45 (Fig. 6A)] caused no further disruption of its ability to stimulate the GTPase rate. To determine the potential participation of the N-terminal half of Pγ in GTPase acceleration, we tested the ability of Pγ46-87 to accelerate GTPase activity. We found a modest (2-fold) decrease in overall affinity of Pγ46-87 with the transducin/RGS9-1 complex (K1/2 = 0.35 ± 0.04 μM) compared to wild-type Pγ (K1/2 = 0.14 ± 0.02 μM). This indicates no significant role for the N-terminal half of Pγ to participate in GTPase acceleration in the Tα*-GTPγS/RGS9-1 complex.

To identify more precisely which regions of Pγ interact with the transducin/RGS9-1 complex to stimulate GTPase activity, we next tested the ability of C-terminal synthetic peptides and N-terminal truncation mutants of Pγ to maximally accelerate the GTPase activity of ROS membrane preparations. We first determined that Pγ65-87 was the minimum C-terminal fragment sufficient to cause maximal stimulation of GTPase activity, since removal of two additional amino acids (Pγ67-87) abolished the potentiating effect entirely (Fig. 6B). To quantitatively define the regions of Pγ that enhance its effectiveness to accelerate GTPase activity, we examined the concentration dependence of this acceleration effect. Whereas Pγ67-87 was completely ineffective at highest concentrations tested (500 μM), adding Thr65 and Val66 enhanced >100-fold the ability of Pγ
to potentiate the GTPase activity of the transducin/RGS9-1 complex (Py65-87, K_{1/2} = 2.5 ± 1.4 μM). Addition of two more amino acids (Py63-87; K_{1/2} = 2.2 ± 0.3 μM) had no effect on the affinity, while inclusion of an additional eight amino acids (Py55-87; K_{1/2} = 0.6 ± 0.2 μM) stabilized the interaction 4-fold. Further elongation of Py had little effect on the ability to stimulate GTPase activity.

Two conclusions arise from these results: (1) Ile86 in conjunction with Thr65 and/or Val66 of Py are required to maximally accelerate the GTPase rate of the Ta*/RGS9-1 complex, consistent with previous evidence (20,23); (2) stabilizing interactions in the region of amino acids 55 to 62 of Py may help anchor Py to the Ta*/RGS9-1 complex even though they are not required for maximal potentiation of the GTPase rate.

Conclusions—This comprehensive analysis of the functionally important regions of the inhibitory γ-subunit that interact with the PDE6 catalytic dimer, with activated transducin α-subunit, and with the Ta*/RGS9-1 complex (summarized in Fig. 7) reveals the complexity of the regulatory mechanisms mediated by multiple regions of this small protein. The ability of the N-terminal and C-terminal regions of Py to span the surface of the Paβ dimer from the GAFa domain to the active site of the catalytic domain underscores the extended linear structure that Py must assume when associated with the Paβ catalytic dimer. Since Py free in solution is a natively unfolded protein (6,51,52), its extended conformation is a consequence of binding to the Paβ dimer at each of the six distinct regions of the Py linear structure (defined in Fig. 7). Because Py seldom (if ever) completely dissociates from Paβ during mammalian visual transduction (53-55), it is likely that the structural elements important for interaction of Py with Ta*, RGS9-1, or other putative binding partners [e.g., GARP2 (56)] occur while Py is associated with the catalytic subunits and involve a disruption of Py-Paβ interactions at the same time as new interactions form between Py and its other binding partners.

Our work reveals the central importance of the glycine-rich region of Py as a primary “docking site” with Paβ (a.a. 52-54), with Ta* (a.a. 54-55), and with the Ta*/RGS9-1 complex (a.a. 55-62; Fig. 7). We hypothesize that this stretch of amino acids stabilizes binding of Ta* to position it to develop additional interactions with the C-terminal “hinge” (a.a. 71-77) and “blocking” (a.a. 78-87) regions of Py (8,24) that lead to de-inhibition of PDE6 catalysis. A subset of residues within the glycine-rich region of Py (specifically a.a. 55-62) is also implicated in facilitating the potentiating role of Py to accelerate GTPase activity of the Ta*/RGS9-1 complex. Further, this same region of Py is implicated in regulating cGMP exchange kinetics at the noncatalytic cGMP binding sites of Paβ. This latter effect may result from another hinge-like mechanism whereby docking of Ta* to the glycine-rich region of Py enables Ta* to form additional, previously identified, interactions with the polycationic region of Py (27-30) which could, in turn, counteract the stabilizing effects of the pro-rich region (a.a. 27-30) of Py on cGMP binding to the GAFa domains of Paβ.

These multiple interactions of Py with Paβ and with other PDE6 binding partners likely occur in a exquisitely controlled temporal sequence that begins with the immediate response to light stimulation of a dark-adapted photoreceptor (i.e., visual excitation leading to PDE6 activation by Ta*). This leads to the subsequent acceleration of photoresponse recovery during light adaptation [RGS9-1-catalyzed acceleration of Ta* GTPase activity being the rate-limiting step; (32)]. Finally, slowly developing aspects of photoreceptor desensitization [reviewed in ref. (2)] may relate to the ability of Ta*-activated PDE6 to increase cGMP dissociation from noncatalytic cGMP binding sites on PDE6 when cytosolic cGMP levels remain low for an extended time. All of these above-mentioned interactions are mediated by changes in Py interactions with Paβ, Ta*, RGS9-1, and other proteins that form a large multiprotein signaling complex on the photoreceptor disk membrane (57). Future efforts will be directed to mapping the individual regions of Py that serve to relay information about the state of light activation from Paβ to the other members of this signaling complex, furthering our understanding of the mechanistic basis for visual dysfunction and photoreceptor...
degeneration that can result from genetic defects in Pγ or its binding partners (4).

FOOTNOTES:
We wish to thank Sue Matte, Karyn Cahill, and Christina Loporcaro for their help with construction of some of the Pγ mutants, protein purification, and manuscript review. This work was supported by National Institutes of Health grant EY-05798. Partial funding was provided by the New Hampshire Agricultural Experiment Station. This is Scientific Contribution Number 2479.

The abbreviations: PDE, cyclic nucleotide phosphodiesterase; PDE6, photoreceptor PDE; Pαβ, catalytic dimer of PDE6 α- and β-subunits; Pγ, inhibitory γ subunit of PDE6; GAF, regulatory domain of PDE6 named for their presence in cGMP regulated PDEs, certain Adenylate cyclases, and the transcription factor Ph1A of bacteria; Tα*, activated transducin α-subunit; a.a., amino acid.

REFERENCES


**Figure Legends**

Figure 1. Multiple regions of Pγ stabilize its interaction with PDE6 catalytic dimer to inhibit catalysis. Purified Pαβ (0.2 nM) was pre-incubated with the indicated N-terminal truncated Pγ mutants (Pγx-87) for 20 min, followed by addition of 2 mM cGMP substrate. Catalytic activity was measured by the phosphate release assay. The inhibition potency (IC₅₀) was calculated from curve fitting the results to a 3-parameter logistic equation. The data represent the mean of at least three experiments; error bars (coefficient of variation < 10 % in all cases) were omitted for clarity. The abscissa represents the position number of the starting amino acid of the N-terminal truncated Pγ mutant, with position 1 being the wild-type sequence. Data for Pγ63-87, Pγ71-87, Pγ74-87, and Pγ78-87 were taken from ref. (10).

Figure 2. An inter-molecular disulfide bond between an N-terminal and C-terminal Pγ fragment enhances the inhibitory potency of the C-terminal region of Pγ. Purified Pαβ (0.2 nM) was pre-incubated with 1 µM Pγ1-68 and increasing concentrations of Pγ68-87 in the presence (△) or absence (□) of 1 mM DTT. The concentration dependence of Pγ68-87 was also assayed in the absence of Pγ1-68 (○). PDE catalytic activity was measured following addition of 2 mM cGMP. The data are the mean ± S.E (n = 4). The lines represent the fit to a 3-parameter logistic equation with IC₅₀ values of: Pγ68-87 alone = 1.0 ± 0.03 µM; +Pγ1-68 plus DTT = 0.8 ± 0.03 µM, and; +Pγ1-68 minus DTT = 0.02 ± 0.001 µM.

Figure 3. Amino acids in the N-terminal portion of Pγ stabilize cGMP binding to the GAF domains of Pαβ. Purified Pαβ (20 nM) was pre-incubated with 10 mM EDTA, 20 mM dipicolinic acid, and 50 µM sildenafil for 2 h at 22°C. [³H]cGMP binding was measured in the presence of increasing amount of the indicated N-terminal truncated Pγ mutants (A) and synthetic peptides (B), and is reported as the percent stimulation of cGMP binding when comparing Pαβ (0% stimulation) to Pαβ incubated with 1 µM wild-type Pγ (100% stimulation, Bmax). The data are the average of at least three experiments, with the curves representing the fit of the data to a hyperbolic function. A. N-terminal truncated Pγ mutants: Pγ1-87 (●), K₁/₂ = 31 ± 10 nM, Bmax = 94%; Pγ18-87 (○), K₁/₂ = 52 ± 13 nM, Bmax = 104%; Pγ21-87 (□), K₁/₂ = 56 ± 11 nM, Bmax = 91%; Pγ27-87 (▼), K₁/₂ = 409 ± 85 nM, Bmax = 98%; Pγ29-87 (▪), K₁/₂ = 457 ± 180 nM, Bmax = 44%. B. Synthetic Pγ peptides: Pγ10-30 (□), K₁/₂ = 10 ± 4.3 µM, Bmax = 107%; Pγ19-30 (●), K₁/₂ = 280 ± 70 µM, Bmax = 47%.

Figure 4. Isoleucine-54 of Pγ is critical for transducin to effectively bind to Pγ to relieve inhibition of catalysis. Purified Pαβ (1 nM) was incubated with the indicated N-terminal truncated Pγ mutants (x-87, where x is the first amino acid position number) in order to suppress 80% or greater of the catalytic activity: 5 nM Pγ1-87; 10 nM Pγ18-87; 0.5 µM Pγ46-87; 1 µM Pγ52-87 and Pγ53-87; 2 µM Pγ54-87; 5 µM Pγ55-87 and Pγ58-87; data for Pγ63-87 was taken from ref. (10)). Following ten min incubation at room temperature, activated transducin (10 µM) was added to one portion of each reconstituted PDE6 preparation, followed by addition of 2 mM cGMP to measure PDE6 catalytic activity. The data are the mean ± S.E.M. for three individual experiments and are reported as the percent of Pαβ activity when no additional Pγ was present.

Figure 5. Interaction of transducin with the glycine-rich region of Pγ increases the rate of cGMP dissociation from PDE6. Nucleotide-depleted Pαβ (20 nM) was pre-incubated with 10 mM EDTA, 20 mM dipicolinic acid, and 50 µM vardenafil for 2 hours at 22°C. [³H]cGMP was added in the presence of 40-80 nM full-length Pγ (A), Pγ1-60 (B) or Pγ1-45 (C), and the samples incubated for 5 min. For each condition, addition of Pγ or truncated mutants stimulated binding 1.5-fold compared to Pαβ dimer alone; the maximum extent of binding (Bmax) just prior to initiating dissociation was Pγ1-87, 1.7 ± 0.2 mol cGMP /mol Pαβ; Pγ1-60, 1.7 ± 0.1 mol cGMP /mol Pαβ; Pγ1-45, 1.6 ± 0.1 mol cGMP /mol Pαβ. [³H]cGMP dissociation was induced by addition of unlabeled cGMP supplemented with or without 2 µM cGMP.
activated transducin (Tα*-GTPγS), and the amount bound (B) assayed at various times thereafter. The data shown in the figure are from one representative experiment, with the results fitted to a single-exponential decay process with t_{1/2} values as follows: A. –Tα* = 26.3 min, +Tα* = 11.2 min; B. –Tα* = 40.5 min, +Tα* = 22.1 min; C. –Tα* = 17.7 min, +Tα* = 15.0 min.

Figure 6. Two major regions of Pγ are critical for the acceleration of GTPase activity of activated transducin. Bovine ROS membranes (containing PDE6, transducin, and RGS9-1) were incubated with Pγ truncation mutants for 20 min at room temperature. GTPase activity was then measured by addition of 0.1 µM [γ-32P]GTP. The reaction was stopped at the indicated time by addition of perchloric acid. GTPase activity is reported as a percent of maximum activity (1 h incubation; >98% substrate hydrolyzed). The data shown in the figure are representative of at least three different experiments, in which the lines represent the fit of the data to a single exponential rise to maximum. A. C-terminal truncated Pγ mutants (2 µM final concentration): no addition (○), t_{1/2} = 8.0 ± 0.8 s; Pγ1-45 (▲), t_{1/2} = 6.2 ± 0.9 s; Pγ1-85 (▽), t_{1/2} = 5.7 ± 0.7 s; Pγ1-86 (◇), t_{1/2} = 3.7 ± 0.4 s; Pγ1-87 (●), t_{1/2} = 3.1 ± 0.8 s. B. N-terminal truncation mutants of Pγ (tested at 10 µM final concentration): no addition (○), t_{1/2} = 8.0 ± 0.8 s; Pγ65-87 (□), t_{1/2} = 3.1 ± 0.3 s; and Pγ67-87 (■), t_{1/2} = 6.8 ± 0.4 s. In all cases except for Pγ67-87, the t_{1/2} values for the indicated Pγ mutants were statistically significant (p < 0.01) compared to the control (no Pγ added).

Figure 7. Functionally important interaction sites of the inhibitory Pγ subunit with PDE6, transducin, and the transducin/RGS9-1 complex. The 87 amino-acid Pγ subunit is defined in terms of six structurally distinct domains: N-terminal region (a.a. 1-19); proline-rich region (a.a. 20-28); polycationic region (a.a. 29-45); glycine-rich region (a.a. 46-62); tryptophan-containing region (a.a. 63-77) and the C-terminal region (a.a. 78-87). The sites that are required for any of the five given functions are shown with solid black boxes. Amino acid residues having major stabilizing effects on Pγ binding to its binding partner are shown in dark grey, while additional, weaker sites of interaction are shown in light grey. The dashed boxes represent critical functional regions of Pγ identified previously (10,20,22,24).
Fig. 1

Inhibition potency (IC50, nM)

N-terminal truncated Pγ mutants (x-87)
Fig. 2
Fig. 3

A

B

Pγ peptides concentration (µM)

cGMP binding (% of maximum stimulation)

Pγ1-87
Pγ18-87
Pγ21-87
Pγ27-87
Pγ29-87
Pγ10-30
Pγ19-30
Fig. 4

PDE activity (% of maximum)

- T-α-GTP

N-terminal truncated P₇ mutants (x-87)

10 18 46 52 53 54 55 58 63

+ T-α-GTP/S

Downloaded from http://www.jbc.org/ by guest on September 1, 2017
Fig. 5

[Graph showing the binding of [3H]cGMP with and without GTPγS and TαGTPγS over time after 1 mM cGMP addition.]

A. Pγ1-87
- TαGTPγS
- +TαGTPγS

B. Pγ1-60
- TαGTPγS
- +TαGTPγS

C. Pγ1-45
- TαGTPγS
- +TαGTPγS

[B/Max] cGMP bound

Time after 1 mM cGMP addition (min)
Fig. 6

GTPase activity (% of maximum)

Time after GTP addition (sec)

A.

B.
Enhances $P\gamma$ inhibition potency

cGMP binding

$T\alpha^*$ activation of PDE6

$T\alpha^*$ enhances cGMP dissociation

GTPase acceleration of $T\alpha^*$
Functional mapping of interacting regions of the photoreceptor phosphodiesterase (PDE6) γ-subunit with PDE6 catalytic dimer, transducin, and Regulator of G-protein Signaling9-1 (RGS9-1)

Xiu-Jun Zhang, Xiong-Zhuo Gao, Wei Yao and Rick H. Cote

J. Biol. Chem. published online June 4, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.377333

Alerts:
  • When this article is cited
  • When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2012/06/04/jbc.M112.377333.full.html#ref-list-1